Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma

Although immunotherapy (anti-PD-1/PD-L1 antibodies) has been approved for clinical treatment of lung cancer, only a small proportion of patients respond to monotherapy. Hence, understanding the regulatory mechanism of PD-L1 is particularly important to identify optimal combinations. In this study, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lin, Xia, Liliang, Ji, Wenxiang, Zhang, Yanshuang, Xia, Weiliang, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215302/
https://www.ncbi.nlm.nih.gov/pubmed/34130052
http://dx.doi.org/10.1016/j.tranon.2021.101148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215302/
https://www.ncbi.nlm.nih.gov/pubmed/34130052
http://dx.doi.org/10.1016/j.tranon.2021.101148

Ejemplares similares